News

Vyvanse is the first and only medication approved for sale in the US for the treatment of this disorder. The approval was based on results from two randomized,

The CRISPR genome-editing tool helps scientists to make changes in specific genes and it has two components, including a homing device to a specific section of DNA (guide-RNA)

MOXIe (A two-part, randomized, placebo-controlled Phase 2/3 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich’s Ataxia) is a multi-center study in

The patent, along with the company’s existing intellectual property, demonstrates VG Life Sciences’ expertise in researching the role of CLIP (class II-associated invariant chain peptide) in chronic inflammatory

PREZCOBIX is a once-daily, fixed-dose antiretroviral combination tablet containing 800 mg of darunavir, marketed as PREZISTA in the United States, and 150 mg of cobicistat, a pharmacokinetic enhancer

This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is currently

The patent will expire no earlier than July 2032. The allowed claims cover a compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors,

Under the deal, Astellas is responsible to develop and commercialize Immunomic’s vaccine candidate JRC2-LAMP-vax, which is designed to treat allergies induced by Japanese red cedar pollen. Both the

Endo president and CEO Rajiv De Silva said: "This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality